Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Actemra® (
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
12:30pm, Friday, 26'th Feb 2021
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) to offer the SAR
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
07:12am, Friday, 26'th Feb 2021
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) confirmed today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a scientific op
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval
Wide-Moat Stocks On Sale - The March 2021 Heat Map
09:27pm, Thursday, 25'th Feb 2021
Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).
Weill Neurohub joins Genentech and Roche in accelerating neuroscience research
03:25pm, Thursday, 25'th Feb 2021
Weill Neurohub is partnering with Genentech and Roche to accelerate research in neuroscience. Former Citigroup chairman and CEO Sandy Weill, Genentech CEO Alexander Hardy and CNBC's Meg Tirrell join '
Roche Reports Positive Evrysdi Data From Dose-Finding Part Of Spinal Muscular Atrophy Trial
01:46pm, Thursday, 25'th Feb 2021
Roche Holding AG (OTCMKTS: RHHBY) has reported positive data from the dose-finding Part 1 FIREFISH Phase 2/3 study of Evrysdi (risdiplam) in infants with symptomatic Type 1 spinal muscular atroph
Weill Neurohub Joins Forces With Genentech and Roche to Advance Neuroscience Research
10:06am, Thursday, 25'th Feb 2021
SAN FRANCISCO--(BUSINESS WIRE)--UCSF, UC Berkeley announce partnership with Genentech to speed development of therapeutics for brain diseases and CNS disorders such as Alzheimer's.
Basel, 25 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine has published Evrysdi™ (risdiplam) data from the dose finding Part 1 of the pivo
Why Turning Point Is Turning Heads
10:59am, Tuesday, 23'rd Feb 2021
This oncology biotech is up over 450% since its April 2019 IPO. Are there still gains to come, or should investors turn away?
ARKG: Precautionary Measures, But Transformational Objectives Remain Intact
09:23am, Monday, 22'nd Feb 2021
Cathie Wood and her team have shown investors that they have the capability to turn double-digit growth dreams into reality.
Your 2 Best Profit Opportunities in 2021
07:40am, Saturday, 20'th Feb 2021
Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.
Analog Devices, Inc's (ADI) CEO Vince Roche on Q1 2021 Results - Earnings Call Transcript
02:55pm, Wednesday, 17'th Feb 2021
Analog Devices, Inc's (ADI) CEO Vince Roche on Q1 2021 Results - Earnings Call Transcript
Biotech Shares Have Soared Since 2020's Wave of IPOs
09:45am, Wednesday, 17'th Feb 2021
Indicative of investors' enthusiasm for new biotechs, the average gain in share price for the top 10 companies of the sector that went public in 2020 now tops 100%.
Roche's Faricimab On Par With Rival Regeneron's Aflibercept In Four Late-Stage Studies In Vision Loss Disorder
12:16pm, Friday, 12'th Feb 2021
Roche Holding's (OCTMKT: RHHBY) bispecific antibody faricimab has matched Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) blockbuster drug, Eylea (aflibercept), in four Phase 3 studies, comparing th
